An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

BACKGROUND: Apalutamide, a nonsteroidal potent androgen receptor antagonist, was safe and effective in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic-CRPC (mCRPC) in global studies. In this phase 1 study, safety, pharmacokinetics (PK), and efficacy of apalu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Clin Oncol
Hlavní autoři: Tsuchiya, Tomohiro, Imanaka, Keiichiro, Iwaki, Yuki, Oyama, Ryo, Hashine, Katsuyoshi, Yamaguchi, Akito, Uemura, Hiroji
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Singapore 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861345/
https://ncbi.nlm.nih.gov/pubmed/31446511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-019-01526-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky